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Patient’s characteristics, drug utilization patterns and resource utilization were 
analyzed. Results: Data were available for a sample of 244 eligible patients. The 
average age of the study population was 24.3 years (SD= 12.5). While the maxi-
mum medication possession ratio (MPR) for alternate month administration is 
50%, patients on TIP had an average MPR of 52.8%, while patients on TIS and OTF 
had an average MPR of 41.4% and 39.7%, respectively. Treatment persistence at 3 
months was estimated at 85.5%, 69.0%, and 65.2% for patients on TIP, TIS, and OTF, 
respectively. Treatment persistence at 6 months was estimated at 78.4%, 62.8%, 
and 56.5%, respectively for patients on TIP, TIS, and OTF. Higher CF medication 
treatment costs with TIP were partially offset by lower costs associated with the 
use of antibiotics, other medications and additional health care resource utiliza-
tion. The median monthly cost per patient in terms of other medications was of 
$1,159 (including $79 for other antibiotics), $1,350 ($172), and $1,495 ($240) for 
patients on TIP, TIS, and OTF, respectively. The median monthly additional health 
care resource utilization cost per patient was estimated at $56, $188, and $220, 
respectively for TIP, TIS and OTF cohorts. ConClusions: In a real life setting, TIP 
was associated with a high level of treatment adherence and limited utilization 
of additional health care resources.
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objeCtives: To determine adherence levels and factors influencing adherence 
to antiretroviral therapy among HIV-infected patients in Venezuela. Methods: 
A sample of 46 HIV-infected HIV patients attending an infectious diseases clinic at 
the Central University of Venezuela were interviewed by the investigators for 20 to 
25 minutes. The interview was guided by a structured questionnaire that included 
questions on sociodemographic and clinical characteristics, medication use, and 
health behaviors. Adherence was assessed retrospectively based on a 4-day recall 
as used in Adult AIDS Clinical Trials Group (AACTG) follow up questionnaire. All 
data analyses were performed using SSPS for Windows Version 19.0. Results: Of 
46 participants, 30 (65.2%) were male and 16 (34.8%) were female. The mean age 
was 43.17 years ( Range 26-73, SD= 9,790). From 46 participants 69.7% reported 
adherence ≥ 95%. Forgetting to take the medications, alcohol use, and problems 
with the medications supply were main barriers for adherence in the present 
study. ConClusions: A group of patients at this clinic reported unsatisfactory 
adherence. Forgetfulness was reported to be the major cause of non-adherence. 
Since adherence to antiretroviral therapy in critical to achieve optimal treatment 
outcomes, health care providers must identify possible barriers to adherence at the 
earliest and provide appropriate solutions.
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objeCtives: Hepatitis C virus (HCV) infection treatment completion is a key success 
factor for achieving optimal clinical outcomes. The objective of this study was to assess 
HCV treatment completion rates in a real life setting. Methods: A retrospective study 
of the Quebec provincial drug reimbursement program (RAMQ) was conducted using 
a random sample of patients who filled at least one script at the pharmacy for an HCV 
medication (pegylated interferon and ribavirin (peg-Riba) +/- boceprevir or telaprevir) 
from January 2007 to December 2012. Treatment completion rates were calculated at 
week 12, 24 and 28 according to HCV medication type in order to assess the proportion of 
patients treated beyond the 12-week futility threshold and the minimal expected treat-
ment duration of 24 weeks (28 weeks for Peg-Riba + boceprevir). Results: A total of 1,081 
patients who used at least one HCV medication were included in the study. The average 
age was 46.4 years (SD= 10.7) and the proportion of men was higher (64.8%). During the 
study period, the number of patients who used Peg-Riba only, Peg-Riba + boceprevir and 
Peg-Riba + telaprevir was 1,029 (95.2%), 50 (4.6%) and 18 (1.7%) respectively. The propor-
tion of patients on Peg-Riba only who completed at least 12 and 24 weeks of treatment 
was 89.7% and 62.2% respectively. There were 96.0% and 58.0% of patients on Peg-Riba 
+ boceprevir who remained on treatment at week 12 and 28 respectively. The percent-
age of patients on Peg-Riba + telaprevir on treatment at week 12 and 24 was 50.0% and 
11.1%, respectively. ConClusions: The proportion of HCV patients who were still on 
treatment decreased with time with high discontinuation rates especially after week 12. 
Treatment completion was not achieved by a significant proportion of patients, regard-
less of HCV medications.
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objeCtives: Over the course of last decade the introduction of highly effective 
antiretroviral (ARV) therapies has transformed a once life-threatening disease into 
a chronic condition. However, maintaining patient adherence to therapy, in the long-
term, is challenging. Despite the enormous benefits offered by current ARVs, evi-
dence suggests that adherence to treatment regimens remains an issue. Numerous 
factors have been identified which compromise long-term adherence, including 
drug-drug interactions, therapy regimen, side-effects, and the overall demands of 
therapy. The aim of this study is to further understanding of the determinants 
of treatment satisfaction for HIV patients receiving ARV therapies. Methods: A 
programme of research was developed in order to firstly establish the relation-
ship between patients’ views of their current therapies and the adherence to ARVs. 
INfectIoN – Patient-reported outcomes & Patient Preference studies
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objeCtives: To determine the comparative effectiveness of different interven-
tions for improving antiretroviral medication adherence in low-income set-
tings. Methods: We obtained individual patient data from all randomized trials 
that have evaluated an adherence intervention to promote antiretroviral adher-
ence within low-income countries. We created a treatment network of the differing 
interventions by pooling the individual patient data from comparable treatments 
and comparing them across the individual interventions using a Bayesian net-
work meta-analysis approach. Outcomes included self-reported adherence and 
viral suppression. Results: We obtained data on 11 randomized, involving 5432 
patients. Interventions included daily and weekly text messaging, calendars, peer 
supporters, alarms, counseling, and basic clinical care. For self-reported adher-
ence, we found compelling evidence for the role of weekly text messages (Odds 
ratio [OR] 1.57, 95% Confidence Intervals [CI] 1.22-2.02), counseling (OR 1.43, 95% CI, 
1.06-1.94), and peer supporters (OR 1.72, 95% CI, 1.28-2.29). We found no compel-
ling evidence for daily text messaging, alarms, calendars, or unsupported clinical 
care. Results were similar when using viral suppression as an outcome, although 
not all trials reported viral outcomes. Treatment supporters (OR 1.36, 95% CI, 1.02-
1.82) and weekly text messages (OR, 1.56, 95% CI, 1.01-2.39) were superior to basic 
clinical care. ConClusions: Using individual patient data allowed us to increase 
precision to determine what interventions appear to work. Several common recom-
mendations for improving adherence are unsupported by the available evidence. 
These findings should influence guidance documents on improving antiretroviral 
adherence in poor settings.
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objeCtives: Adherence to ART is a key success factor for achieving optimal 
clinical outcomes in HIV disease. The objective was to assess differences in 
compliance rates and health care resource utilization between patients receiv-
ing a once daily single tablet regimen (STR) vs. a multiple tablets per day regi-
men (MTR). Methods: This retrospective study included patients covered by 
the Quebec provincial drug reimbursement program (RAMQ) who have received 
at least one script for an ART from January 1st, 2006 to June 30th, 2012. For each 
patient, the index date was defined as the date of the first script for an ART and 
compliance rates were estimated over a 1-year period. Patients were considered 
compliant if their medication possession ratio (effective treatment duration 
over expected treatment duration) was equal or greater to 90%. Medical costs 
(hospitalizations and ER, outpatient clinic, ICU and physician’s visits) were com-
pared between the STR group vs. the MTR group. Regression analyses were per-
formed to assess the relationship between compliance, hospitalization rates and 
medical costs with the ART regimen, adjusting for age, gender, comorbidities 
scores, mental disorders diagnosis and drug and alcohol abuses. Results: The 
study included 4,996 HIV patients (mean age: 42.4 years, 74.8% males). A higher 
proportion of patients were compliant (88.4% vs. 75.8%) in the STR group com-
pared to the MTR group (p< 0.001). Patients receiving a MTR were 2.0-fold more 
likely to be non-compliant than patients receiving a STR (p< 0.001). Moreover, 
hospitalization rates (25.8% vs. 15.9%, p< 0.001) and medical costs (CAD$2,785 
vs. CAD$1,909, p= 0.008) were higher for patients receiving a MTR than a 
STR. Linear regression analyses also showed a positive relationship between 
MTR (vs. STR) and hospitalization rates (β = 0.081,p= 0.001) and medical costs 
(β = 0.151, p< 0.001). ConClusions: Patients receiving a STR are more 
compliant than patients on a MTR and have lower hospitalization rates and 
medical costs.
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objeCtives: To describe treatment patterns and measure real-world outcomes 
with tobramycin powder for inhalation (TIP), tobramycin inhalation solu-
tion (TIS), and other tobramycin formulations (OTF), using the provincial pub-
lic drug reimbursement program database of the Régie de l’assurance maladie du 
Québec(RAMQ). Methods: Patients with a diagnosis of CF covered by the RAMQ 
drug reimbursement program who had used TIP, TIS, or OTF on at least one 
occasion during the period from January 1st 2011 to June 30th 2012 were selected. 
